Forward Ventures
Forward Ventures ic a venture capital company that focuses in companies in the area of biological sciences.
Business Model:
Revenue: $18.6M
Employees: 11-50
Rankings
Industries / Tags:
Detailed Forward Ventures Information
Geographic Data
Address: 9255 Towne Centre Drive Suite 350San
City:
State: CA
Zip: 92121
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Forward Ventures, founded in 1993, is a leading life-science venture capital firm located in San Diego. Forward has a team of investment professionals with extensive experience in entrepreneurship, venture capital and operations. Our firm has invested in over 50 companies since it was founded in 1993 and currently has more than $500 million in capital under management. The most recent fund, Forward V, continues Forward Ventures’ program of life sciences and health care venture investing in companies of all stages of development. Forward invests throughout the United States and will consider select European opportunities.
Contact Phone:
+18586776077
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 3/2003 | Hypnion | Series B | 47.5M |
| 7/2007 | TargeGen | Series D | 40M |
| 8/2019 | Virtuozo | Seed Round | 0 |
| 11/2002 | Kemia | Series A | 16.5M |
| 11/2022 | Xanadu | Series C | 0 |
| 2/2010 | Altair Therapeutics | Series B | 17M |
| 10/2005 | Nereus Pharmaceuticals | Series D | 0 |
| 12/2000 | Ambit Biosciences | Series B | 18.8M |
| 8/2007 | Nereus Pharmaceuticals | Series D | 0 |
| 4/2017 | Viracta Therapeutics | Series B | 0 |
| 10/2007 | Concurrent Thinking | Venture Round | 3.2M |
| 5/2005 | Ambit Biosciences | Series C | 31M |
| 5/2001 | AGY | Series B | 13M |
| 11/2007 | Viracta Therapeutics | Series A | 20M |
| 3/2007 | Affinium Pharmaceuticals | Series A | 18M |
| 9/2003 | NovaCardia | Venture Round | 22M |
| 4/2010 | Viracta Therapeutics | Series B | 12M |
| 9/2005 | TargeGen | Series C | 30M |
| 8/2005 | Adiana | Series D | 23M |
| 1/2005 | Predix Pharmaceuticals | Series C | 0 |
| 4/2002 | Micromet | Series B | 0 |
| 1/2002 | Gryphon Therapeutics | Series B | 26M |
| 5/2002 | TargeGen | Series A | 10M |
| 11/2007 | Asteres | Series C | 4M |
| 1/2007 | Proprius Pharmaceuticals | Series A | 0 |
| 1/2004 | TargeGen | Series B | 30M |
| 2/2010 | Tioga Pharmaceuticals | Venture Round | 18M |
| 8/2003 | Micromet | Series C | 0 |
| 8/2011 | Affinium Pharmaceuticals | Series B | 0 |
| 3/2012 | Viracta Therapeutics | Series B | 0 |
| 8/2006 | Kemia | Series C | 0 |
| 1/1995 | Corixa | Series A | 15M |
| 11/2003 | Sanarus Medical | Series C | 19.1M |
| 4/2002 | Dynavax Technologies | Series D | 0 |
| 11/2012 | Ambit Biosciences | Venture Round | 0 |
| 5/2003 | Acorda Therapeutics | Series B | 55.3M |
| 1/2006 | Tioga Pharmaceuticals | Series A | 24M |
| 6/2011 | Ambit Biosciences | Series D | 0 |
| 7/2001 | Sanarus Medical | Series B | 13.8M |
| 9/2007 | Sequel Pharmaceuticals | Series A | 20M |
| 4/2007 | NovaCardia | Series B | 18M |
| 6/2010 | Nereus Pharmaceuticals | Series E | 0 |
| 9/2013 | Affinium Pharmaceuticals | Debt Financing | 0 |
| 4/2004 | Imagine Pharmaceuticals | Series A | 3.7M |
| 3/2004 | Kemia | Series B | 33.5M |
| 8/2015 | Syndax Pharmaceuticals | Series C | 0 |
| 9/2003 | Conforma Therapeutics | Series C | 30M |
| 4/2005 | Sanarus Medical | Series D | 23M |
| 10/2006 | Morphotek | Series D | 0 |
| 12/2005 | Hypnion | Series B | 0 |
| 11/2007 | Ambit Biosciences | Series D | 49.3M |
| 3/2008 | LigoCyte Pharmaceuticals | Series C | 29.5M |
| 4/2007 | Syndax Pharmaceuticals | Series A | 40M |
| 3/2010 | Syndax Pharmaceuticals | Series A | 9M |
| 8/2013 | Syndax Pharmaceuticals | Series B | 0 |
| 2/2004 | Morphotek | Series C | 26M |
| 2/2007 | Sanarus Medical | Series E | 15M |
| 9/2004 | Cellective Therapeutics | Series A | 27.5M |
| 8/2006 | Cabrellis Pharmaceuticals | Series A | 27.5M |
| 1/2001 | Acorda Therapeutics | Series A | 0 |
| 4/2005 | NovaCardia | Series A | - |
| 9/2006 | NovaCardia | Series B | 48M |
| 3/2000 | Variagenics | Funding Round | 19M |
| 11/2022 | Xanadu | Series C | 0 |
| 8/2019 | Virtuozo | Seed Round | 0 |
| 4/2017 | Viracta Therapeutics | Series B | 0 |
| 8/2015 | Syndax Pharmaceuticals | Series C | 0 |
| 9/2013 | Affinium Pharmaceuticals | Debt Financing | 0 |
| 8/2013 | Syndax Pharmaceuticals | Series B | 0 |
| 11/2012 | Ambit Biosciences | Venture Round | 0 |
| 3/2012 | Viracta Therapeutics | Series B | 0 |
| 8/2011 | Affinium Pharmaceuticals | Series B | 0 |
| 6/2011 | Ambit Biosciences | Series D | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
